Pharmala Biotech Holdings Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Feb '25 Feb 28, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022
Net Income	-1.93	-0.82	-0.78	-0.99
Depreciation & Amortization	0	0.01	0	0.01
Other Amortization	0.1	0.06	0.05	-
Stock-Based Compensation	1.24	0.65	0.07	0.24
Provision & Write-off of Bad Debts	0.02	0.02	0.02	-
Other Operating Activities	0.17	0.16	-0.07	-
Change in Accounts Receivable	0.03	-0.01	-0.11	-0.02
Change in Inventory	-0.33	-0.23	-0.01	-0.12
Change in Accounts Payable	-0.27	-0.03	0.21	0.23
Change in Unearned Revenue	-	-	-	0.05
Change in Other Net Operating Assets	0.23	-0.12	0.28	-0.03
Operating Cash Flow	-0.72	-0.32	-0.34	-0.63
Capital Expenditures	-	-	-	-0
Sale (Purchase) of Intangibles	-0.11	-0.23	-0.51	-0.99
Investing Cash Flow	-1.36	-0.23	-0.51	-0.99
Issuance of Common Stock	2.39	0.83	0.19	-
Other Financing Activities	-0.08	-0.05	-	-
Financing Cash Flow	2.3	0.77	0.19	-
Net Cash Flow	0.23	0.22	-0.66	-1.62
Free Cash Flow	-0.72	-0.32	-0.34	-0.63
Free Cash Flow Margin	-167.56%	-31.04%	-63.84%	-804.87%
Free Cash Flow Per Share	-0.01	-0.00	-0.00	-0.01
Levered Free Cash Flow	-0.16	-0.08	-0.48	-
Unlevered Free Cash Flow	-0.16	-0.08	-0.48	-
Change in Net Working Capital	0.26	0.22	-0.32	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.